Literature DB >> 21119732

Vitamin D, disease and therapeutic opportunities.

Lori A Plum1, Hector F DeLuca.   

Abstract

The discovery of the vitamin D endocrine system and a receptor for the hormonal form, 1α,25-dihydroxyvitamin D(3), has brought a new understanding of the relationship between vitamin D and metabolic bone diseases, and has also established the functions of vitamin D beyond the skeleton. This has ushered in many investigations into the possible roles of vitamin D in autoimmune diseases, cardiovascular disorders, infectious diseases, cancers and granuloma-forming diseases. This article presents an evaluation of the possible roles of vitamin D in these diseases. The potential of vitamin D-based therapies in treating diseases for which the evidence is most compelling is also discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119732     DOI: 10.1038/nrd3318

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  161 in total

Review 1.  1,25-Dihydroxyvitamin D3 and the skin: a unique application for the treatment of psoriasis.

Authors:  M F Holick
Journal:  Proc Soc Exp Biol Med       Date:  1989-07

2.  A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.

Authors:  Hua Zhu Ke; Hong Qi; D Todd Crawford; Hollis A Simmons; Gang Xu; Mei Li; Lori Plum; Margaret Clagett-Dame; Hector F DeLuca; David D Thompson; Thomas A Brown
Journal:  J Bone Miner Res       Date:  2005-06-13       Impact factor: 6.741

3.  Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.

Authors:  Gary G Schwartz; M Craig Hall; Diana Stindt; Suzanne Patton; James Lovato; Frank M Torti
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

4.  Diet and the geographical distribution of multiple sclerosis.

Authors:  B W Agranoff; D Goldberg
Journal:  Lancet       Date:  1974-11-02       Impact factor: 79.321

5.  Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma.

Authors:  N A Breslau; J L McGuire; J E Zerwekh; E P Frenkel; C Y Pak
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

6.  Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator.

Authors:  J N Barker; R E Ashton; R Marks; R I Harris; J Berth-Jones
Journal:  Br J Dermatol       Date:  1999-08       Impact factor: 9.302

7.  A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections.

Authors:  M Li-Ng; J F Aloia; S Pollack; B A Cunha; M Mikhail; J Yeh; N Berbari
Journal:  Epidemiol Infect       Date:  2009-03-19       Impact factor: 2.451

8.  Characterization of a receptor-like protein for 1,25-dihydroxyvitamin D3 in rat skin.

Authors:  R U Simpson; H F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat.

Authors:  G Sjöden; C Smith; U Lindgren; H F DeLuca
Journal:  Proc Soc Exp Biol Med       Date:  1985-03

10.  Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.

Authors:  Cheuk-Chun Szeto; Kai-Ming Chow; Bonnie Ching-Ha Kwan; Kwok-Yi Chung; Chi-Bon Leung; Philip Kam-Tao Li
Journal:  Am J Kidney Dis       Date:  2008-04-03       Impact factor: 8.860

View more
  142 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

2.  Design, synthesis, and biological action of 20R-hydroxyvitamin D3.

Authors:  Yan Lu; Jianjun Chen; Zorica Janjetovic; Phillip Michaels; Edith K Y Tang; Jin Wang; Robert C Tuckey; Andrzej T Slominski; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2012-03-20       Impact factor: 7.446

3.  Total synthesis of biologically active 20S-hydroxyvitamin D3.

Authors:  Qinghui Wang; Zongtao Lin; Tae-Kang Kim; Andrzej T Slominski; Duane D Miller; Wei Li
Journal:  Steroids       Date:  2015-10-01       Impact factor: 2.668

Review 4.  Vitamin D: Implications for ocular disease and therapeutic potential.

Authors:  Rose Y Reins; Alison M McDermott
Journal:  Exp Eye Res       Date:  2015-02-25       Impact factor: 3.467

Review 5.  Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism.

Authors:  Stefania Giuliana Garbossa; Franco Folli
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

6.  A report from Fukushima: an assessment of bone health in an area affected by the Fukushima nuclear plant incident.

Authors:  Takeaki Ishii; Kazuo Ito; Shigeaki Kato; Masaharu Tsubokura; Sae Ochi; Yukihide Iwamoto; Yasutoshi Saito
Journal:  J Bone Miner Metab       Date:  2013-08-08       Impact factor: 2.626

7.  Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies.

Authors:  Dan Wang; Omar Israel Vélez de-la-Paz; Jun-Xia Zhai; Dian-Wu Liu
Journal:  Tumour Biol       Date:  2013-06-27

Review 8.  Biology and Mechanisms of Action of the Vitamin D Hormone.

Authors:  J Wesley Pike; Sylvia Christakos
Journal:  Endocrinol Metab Clin North Am       Date:  2017-09-29       Impact factor: 4.741

Review 9.  Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Judith V Hobrath; Allen S W Oak; Edith K Y Tang; Elaine W Tieu; Wei Li; Robert C Tuckey; Anton M Jetten
Journal:  J Steroid Biochem Mol Biol       Date:  2016-09-28       Impact factor: 4.292

Review 10.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.